<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37344934</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-6924</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Risk analysis : an official publication of the Society for Risk Analysis</Title><ISOAbbreviation>Risk Anal</ISOAbbreviation></Journal><ArticleTitle>Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.</ArticleTitle><Pagination><StartPage>366</StartPage><EndPage>378</EndPage><MedlinePgn>366-378</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/risa.14158</ELocationID><Abstract><AbstractText>Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global Polio Eradication Initiative (GPEI) coordinated cessation of Sabin type 2 OPV (OPV2 cessation) in 2016, except for emergency outbreak response. However, as of early 2023, plans for cessation of bivalent OPV (bOPV, containing types 1 and 3 OPV) remain undefined, and OPV2 use for outbreak response continues due to ongoing transmission of type 2 polioviruses and reported type 2 cases. Recent development and use of a genetically stabilized novel type 2 OPV (nOPV2) leads to additional potential vaccine options and increasing complexity in strategies for the polio endgame. Prior applications of integrated global risk, economic, and poliovirus transmission modeling consistent with GPEI strategic plans that preceded OPV2 cessation explored OPV cessation dynamics and the evaluation of options to support globally coordinated risk management efforts. The 2022-2026 GPEI strategic plan highlighted the need for early bOPV cessation planning. We review the published modeling and explore bOPV cessation immunization options as of 2022, assuming that the GPEI partners will not support restart of the use of any OPV type in routine immunization after a globally coordinated cessation of such use. We model the potential consequences of globally coordinating bOPV cessation in 2027, as anticipated in the 2022-2026 GPEI strategic plan. We do not find any options for bOPV cessation likely to succeed without a strategy of bOPV intensification to increase population immunity prior to cessation.</AbstractText><CopyrightInformation>© 2023 Society for Risk Analysis. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk Inc., Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-1015-4818</Identifier><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4900-9455</Identifier><AffiliationInfo><Affiliation>Kid Risk Inc., Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0849-9147</Identifier><AffiliationInfo><Affiliation>Kid Risk Inc., Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NU2RGH001915</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Risk Anal</MedlineTA><NlmUniqueID>8109978</NlmUniqueID><ISSNLinking>0272-4332</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">polio</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37344934</ArticleId><ArticleId IdType="mid">NIHMS1911576</ArticleId><ArticleId IdType="pmc">PMC10733544</ArticleId><ArticleId IdType="doi">10.1111/risa.14158</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Global eradication of poliomyelitis: Report of the second meeting of the Global Technical Consultative Group (TCG), 28
April
1997. 1997 [cited 2023 February 24, 2003]; Available from: https://apps.who.int/iris/bitstream/handle/10665/63994/WHO_EPI_GEN_98.04.pdf.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, et al., Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal, 2006. 26(6): p. 1471–505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>John TJ, Two good reasons to drop type 2 virus from oral polio vaccine. Lancet, 2004. 364(9446): p. 1666.</Citation><ArticleIdList><ArticleId IdType="pubmed">15530625</ArticleId></ArticleIdList></Reference><Reference><Citation>John TJ and Dharmapalan D, Challenges en route to polio eradication. Lancet, 2022. 400(10350): p. 428–429.</Citation><ArticleIdList><ArticleId IdType="pubmed">35835128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K, et al., Vaccination against polio should not be stopped. Nat Rev Microbiol, 2007. 5(12): p. 952–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965726</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K, et al., Polio eradication at the crossroads. Lancet Glob Health, 2021. 9(8): p. e1172–e1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">34118192</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffe AM, et al., NIAID workshop on secondary vaccine effects. Nat Immunol, 2021. 22(11): p. 1363–1366.</Citation><ArticleIdList><ArticleId IdType="pubmed">34686866</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K, et al., Can existing live vaccines prevent COVID-19? Science, 2020. 368(6496): p. 1187–1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">32527819</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaby P, et al., Oral polio vaccination and low case fatality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine, 2004. 22(23–24): p. 3014–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297050</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Badizadegan K, Health economic analyses of secondary vaccine effects: a systematic review and policy insights. Expert Rev Vaccines, 2022. 21(3): p. 297–312.</Citation><ArticleIdList><ArticleId IdType="pubmed">34927511</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States. Risk Anal, 2021. 41(2): p. 376–386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983986</ArticleId><ArticleId IdType="pubmed">33084153</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]. Risk Anal, 2021. 41(2): p. 389–392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014295</ArticleId><ArticleId IdType="pubmed">33590518</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA, Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines, 2020. 19(7): p. 661–686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, et al., The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health, 2008. 98(7): p. 1322–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424088</ArticleId><ArticleId IdType="pubmed">18511720</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med, 2008. 10(8): p. 190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562150</ArticleId><ArticleId IdType="pubmed">18924642</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ, and Pallansch MA, Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal, 2006. 26(6): p. 1541–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184396</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1), WHO, Geneva, 19–24
May
2008. 2008 February 24, 2023]; Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf.</Citation></Reference><Reference><Citation>Thompson KM and Tebbens RJ, Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines, 2012. 11(4): p. 449–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">22551030</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, et al., An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis, 2015. 15: p. 389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, et al., Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis, 2016. 16: p. 137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis, 2014. 210 Suppl 1: p. S475–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316870</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM, Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis, 2014. 210 Suppl 1: p. S485–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316871</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Part 1: General SOPs. 2016. 
February
24, 2023]; Available from: https://s3.amazonaws.com/gpei-tk/reference_links/en/GPEI_SOPs.pdf.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, and Thompson KM, Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis, 2016. 16: p. 237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, and Thompson KM, Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis, 2016. 16: p. 231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880825</ArticleId><ArticleId IdType="pubmed">27230071</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes. J Infect Dis, 2017. 216(suppl_1): p. S168–S175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM, Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines, 2018. 17(8): p. 739–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Risk Anal, 2021. 41(2): p. 248–265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Risk Anal, 2021. 41(2): p. 320–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Polio eradication: what kind of world do we want? Lancet Infect Dis, 2022. 22(2): p. 161–163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504921</ArticleId><ArticleId IdType="pubmed">34648732</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, et al., Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science, 2020. 368(6489): p. 401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA, Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal, 2021. 41(2): p. 229–247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983882</ArticleId><ArticleId IdType="pubmed">32339327</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame Strategic Plan (2013–2018). Geneva; 2013. Report No: WHO/POLIO/13.02 2013 [cited 2019 Jun 4]; Available from: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf [Accesssed February 24, 2023].</Citation></Reference><Reference><Citation>Kalkowska DA and Thompson KM, Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019–2029. Risk Anal, 2021. 41(2): p. 364–375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895457</ArticleId><ArticleId IdType="pubmed">33590519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Anal, 2021. 41(2): p. 329–348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Modeling and Managing Poliovirus Risks: We are Where we are. Risk Anal, 2021. 41(2): p. 223–228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894995</ArticleId><ArticleId IdType="pubmed">33590520</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowsa DA, and Badizadegan K, ooking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation Front Public Health, 2023. 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080024</ArticleId><ArticleId IdType="pubmed">37033033</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. 2023. 
April
3, 2023]; Available from: https://polioeradication.org/wp-content/uploads/2023/03/weekly-polio-analyses-cVDPV-20230328.pdf.</Citation></Reference><Reference><Citation>Konopka-Anstadt JL, et al., Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines, 2020. 5(1): p. 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, et al., Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe, 2020. 27(5): p. 736–751 e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines, 2021. 20(4): p. 449–460.</Citation><ArticleIdList><ArticleId IdType="pubmed">33599178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine, 2023. 41 Suppl 1: p. A12–A18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045205</ArticleId><ArticleId IdType="pubmed">33962838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine, 2023. 41 Suppl 1: p. A136–A141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11027208</ArticleId><ArticleId IdType="pubmed">33994237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine, 2023. 41 Suppl 1: p. A142–A152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284582</ArticleId><ArticleId IdType="pubmed">36402659</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization and UNICEF. 17th WHO/UNICEF Consultation with OPV/IPV Manufacturers and National Authorities for Containment of Polio Vaccine Producing Countries. 2018. 
February
21, 2019]; Available from: http://polioeradication.org/wp-content/uploads/2018/11/2018_WHO_UNICEF_Consultation_Mtg_Report_FINAL.pdf.</Citation></Reference><Reference><Citation>Macklin GR, et al., Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine, 2023. 41 Suppl 1: p. A122–A127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. GPEI consultation with OPV/IPV manufacturers, national authorities for containment and national regulatory authorities. 2020. 
September
29, 2022]; Available from: https://polioeradication.org/wp-content/uploads/2022/01/2020-GPEI-Consultation-with-OPV-IPV-Manufacturers-NACs-NRAs.pdf.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, et al., Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations. Risk Anal, 2018. 38(8): p. 1701–1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879700</ArticleId><ArticleId IdType="pubmed">29314143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, and Thompson KM, Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. Risk Anal, 2022: p. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780402</ArticleId><ArticleId IdType="pubmed">35739080</ArticleId></ArticleIdList></Reference><Reference><Citation>Web Relief. UNICEF Yemen humanitarian situation report: 1 – 31 March 2022. 2022. 
June
7, 2022]; Available from: https://reliefweb.int/report/yemen/unicef-yemen-humanitarian-situation-report-1-31-march-2022.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Somalia. 2022. 
October
4, 2022]; Available from: https://polioeradication.org/where-we-work/somalia/.</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: Delivering on a promise. 2021. 
Feb
24, 2022]; Available from: https://polioeradication.org/wp-content/uploads/2022/06/Polio-Eradication-Strategy-2022-2026-Delivering-on-a-Promise.pdf.</Citation></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, Health economic analysis of vaccine options for the polio eradication endgame: 2022–2036. Expert Rev Vaccines, 2022. 21(11): p. 1667–1674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10116513</ArticleId><ArticleId IdType="pubmed">36154436</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM, Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis, 2015. 15: p. 390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582727</ArticleId><ArticleId IdType="pubmed">26404780</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis, 2015. 15: p. 376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574692</ArticleId><ArticleId IdType="pubmed">26382234</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis, 2015. 15: p. 374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574397</ArticleId><ArticleId IdType="pubmed">26381878</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebbens RJD, et al., Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. J Vaccines Vaccin, 2016. 7(5): p. 340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, and Thompson KM, Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis, 2018. 18(1): p. 165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892013</ArticleId><ArticleId IdType="pubmed">29631539</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission. J Infect Dis, 2017. 216(suppl_1): p. S176–S182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Report from the Twentieth Meeting of the Global Commission for Certification of Poliomyelitis Eradication, Geneva, Switzerland, 17–18
October
2019. 2019 Dec 31, 2019]; Available from: http://polioeradication.org/wp-content/uploads/2016/07/20th-meeting-of-the-Global-Commission-for-the-Certification-of-Eradication-of-Poliomyelitis-17-18-October-2019.pdf.</Citation></Reference><Reference><Citation>Kalkowska DA, et al., Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis, 2015. 15: p. 66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344758</ArticleId><ArticleId IdType="pubmed">25886823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan. Risk Anal, 2019. 39(2): p. 402–413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842182</ArticleId><ArticleId IdType="pubmed">30296340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, and Thompson KM, Environmental Surveillance System Characteristics and Impacts on Confidence About No Undetected Serotype 1 Wild Poliovirus Circulation. Risk Anal, 2019. 39(2): p. 414–425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857156</ArticleId><ArticleId IdType="pubmed">30239023</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, and Thompson KM, Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission. BMJ Open, 2019. 9(1): p. e023938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340450</ArticleId><ArticleId IdType="pubmed">30647038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA and Thompson KM, Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. Risk Anal, 2021. 41(2): p. 312–319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887090</ArticleId><ArticleId IdType="pubmed">32936466</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Wild poliovirus list: List of wild poliovirus by country and year. 2023. 
April
3, 2023]; {Kalkowsa, 2023 #578}:[Available from: https://polioeradication.org/polio-today/polio-now/wild-poliovirus-list/.</Citation></Reference><Reference><Citation>Kalkowska DA, et al., Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options. J Infect Dis, 2021. 224(9): p. 1529–1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083227</ArticleId><ArticleId IdType="pubmed">33885734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, and Thompson KM, Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. Risk Anal, 2022: p. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780400</ArticleId><ArticleId IdType="pubmed">35739067</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Meeting of the Strategic Advisory Group of Experts on immunization, April 2022: conclusions and recommendations. Weekly Epidemiological Record, 2022. 97(24): p. 274–275.</Citation></Reference><Reference><Citation>Sangrujee N, et al., Policy decision options during the first 5 years following certification of polio eradication. MedGenMed, 2003. 5(4): p. 35.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745382</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA, Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Rev Vaccines, 2019. 18(7): p. 725–736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816497</ArticleId><ArticleId IdType="pubmed">31248293</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, et al., Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal, 2013. 33(4): p. 516–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941951</ArticleId><ArticleId IdType="pubmed">23461599</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines, 2014. 13(2): p. 221–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24308581</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Meeting of the Strategic Advisory Group of Experts on immunization, October 2014 - conclusions and recommendations. Weekly Epidemiological Record, 2014. 89(50): p. 561–576.</Citation><ArticleIdList><ArticleId IdType="pubmed">25513671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowsa DA, et al., Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. Gates Open Res, 2023: p. accepted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10403636</ArticleId><ArticleId IdType="pubmed">37547300</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations. Wkly Epidemiol Rec, 2015. 90(50): p. 681–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">26685390</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 14th Meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC), Bali, Indonesia, 20–21
September, 2015. 
Summary of findings, decisions and recommendations. 2015 Jul 22, 2021]; Available from: http://polioeradication.org/wp-content/uploads/2016/07/1Report.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Report from the Twenty-second Meeting of the Global Commission for Certification of Poliomyelitis Eradication, Geneva, Switzerland, 3
June
2022. 2022 September 12, 2022]; Available from: https://polioeradication.org/wp-content/uploads/2022/09/22nd-GCC-report-20220907.pdf.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, et al., A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol, 2005. 162(4): p. 358–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014773</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, et al., Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep, 2012. 127(1): p. 23–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234395</ArticleId><ArticleId IdType="pubmed">22298920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al., Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis, 2015. 211(11): p. 1800–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Duintjer Tebbens RJ, Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine, 2015. 33(13): p. 1568–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907970</ArticleId><ArticleId IdType="pubmed">25701673</ArticleId></ArticleIdList></Reference><Reference><Citation>United Kingdom Department of Health &amp; Social Care. Joint Committee on Vaccination and Immunisation statement on vaccination strategy for the ongoing polio incident. 2022. 
Aug
24, 2022]; Available from: https://www.gov.uk/government/publications/vaccination-strategy-for-ongoing-polio-incident-jcvi-statement/joint-committee-on-vaccination-and-immunisation-statement-on-vaccination-strategy-for-the-ongoing-polio-incident.</Citation></Reference><Reference><Citation>Zuckerman NS, et al., Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill, 2022. 27(37).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9479469</ArticleId><ArticleId IdType="pubmed">36111556</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, et al., Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep, 2022. 71(33): p. 1065–1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson AB, et al., Wastewater Testing and Detection of Poliovirus Type 2 Genetically Linked to Virus Isolated from a Paralytic Polio Case - New York, March 9-October 11, 2022. MMWR Morb Mortal Wkly Rep, 2022. 71(44): p. 1418–1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Interim guidance on the use of novel oral polio vaccine type 2 (nOPV2) for the response to type 2 circulating vaccine-derived poliovirus (cVDPV2) during the initial use period (Addendum to the standard operating procedures for response to a poliovirus event or outbreak, version 3.1). 2020. 
Nov
7, 2022]; Available from: https://polioeradication.org/wp-content/uploads/2020/11/EN-interim-Guidance-on-the-use-of-nOPV2-during-the-initial-use-period-Oct2020.pdf.</Citation></Reference><Reference><Citation>Thompson KM and Kalkowska DA, Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Anal, 2021. 41(2): p. 349–363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984393</ArticleId><ArticleId IdType="pubmed">32645244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortner R, Has the billion dollar crusade to eradicate polio come to an end? BMJ, 2021. 374: p. n1818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778582</ArticleId><ArticleId IdType="pubmed">34321214</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM, Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Rev Vaccines, 2017. 16(6): p. 577–586.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>